Telomir Pharmaceuticals (NASDAQ: TELO) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Telomir-1 (Telomir-Zn), targeting advanced and metastatic triple-negative breast cancer (TNBC). The IND submission is backed by preclinical efficacy and safety data demonstrating tumor growth reduction and favorable tolerability. Pending IND clearance, the company plans to initiate a Phase 1/2 clinical trial evaluating the oral therapy, with a focus on safety, dose optimization, and early signs of antitumor activity.
Triple-negative breast cancer is an aggressive subtype that lacks targeted treatment options, leading to a significant unmet medical need. Telomir-1 represents a novel epigenetic approach aimed at addressing this challenge by modulating fundamental mechanisms implicated in cancer progression. The preclinical data supporting the IND application showed that Telomir-1 reduced tumor growth in animal models while maintaining a favorable safety profile, which is critical for advancing to human trials.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target epigenetic and metabolic mechanisms involved in cancer, aging, and degenerative disease. The company's lead program, Telomir-1, has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. This multifaceted approach aims to address the underlying drivers of disease rather than just symptoms.
The IND submission marks a key milestone for Telomir as it transitions from preclinical development to clinical testing. If the IND is cleared, the Phase 1/2 trial will assess safety and tolerability in patients with advanced or metastatic TNBC, with dose optimization and preliminary antitumor activity as secondary endpoints. The study is expected to enroll patients who have progressed on standard therapies, highlighting the potential for Telomir-1 to fill a critical gap in TNBC treatment.
Investors and stakeholders can find the latest news and updates regarding Telomir Pharmaceuticals in the company's newsroom at https://ibn.fm/TELO. The full press release detailing the IND submission is available at https://ibn.fm/CgUik.
Telomir's advancement into clinical trials underscores the growing interest in epigenetic therapies for hard-to-treat cancers. By targeting fundamental cellular processes, Telomir-1 may offer a new avenue for patients with limited options. The company's focus on TNBC, a disease with high relapse rates and poor prognosis, positions it to address a significant area of unmet need. As Telomir progresses its clinical program, the outcomes of the Phase 1/2 trial will be closely watched by the oncology community and investors alike.
